Close X
Get more out of WDDTY.com
by joining the site for free
Free 17-point plan to great health
Twice weekly e-news bulletins
Access to our News, Forums and Blogs
Sign up for free and claim your
17-point plan to great health
Free 17-point plan to great health

Twice weekly e-news bulletins

Access to our News, Forums and Blogs
OR

If you want to read our in-depth research articles or
have our amazing magazine delivered to your home
each month, then you have to pay.


Click here if you're interested
Helping you make better health choices

What Doctors Don't Tell You

In shops now or delivered to your home from only £4.25 an issue!

Subscribe!
October 2020 (Vol. 5 Issue 7)

Most high-risk heart patients not helped by statins
About the author: 
Bryan Hubbard

Most high-risk heart patients not helped by statins image

Most people who are at risk of developing heart disease aren't being helped by cholesterol-lowering statins. The drugs failed to reduce levels of 'bad' LDL cholesterol in 58 per cent of at-risk patients, new research has discovered.

The findings echo those in a study last month that had found the drugs are ineffective in 50 per cent of patients.

In the new study, the drugs failed to reduce LDL cholesterol to safe levels in most at-risk patients, and 51 per cent of those who took the drugs as prescribed, while 33 per cent of the 86,000 patients monitored didn't see their LDL levels fall.

Statins are the first-line therapy for people with raised levels of LDL cholesterol—but they're not working, say the researchers from the University of North Carolina. They analysed the health records of all heart patients taking statins in the state of Indiana.

Around 1,173 new cases of heart disease could be prevented if the statins did their job properly, the researchers reckon.

Surprisingly, the research was paid for by Merck, the drug giant that makes the statin blockbuster Zocor. Most company-funded trials come up with results that support the drug—so does Merck have something waiting in the wings following the failure of its breakthrough drug, anacetrapib, heralded as a new way of reducing cholesterol?


References

(Source: Journal of Managed Care & Specialty Pharmacy, 2019; 25: 544)

You may also be interested in...

Support WDDTY

Help support us to hold the drugs companies, governments and the medical establishment accountable for what they do.

Advertisements

Latest Tweet

About

Since 1989, WDDTY has provided thousands of resources on how to beat asthma, arthritis, depression and many other chronic conditions..

Start by looking in our fully searchable database, active and friendly community forums and the latest health news.

Positive SSL Wildcard

Facebook Twitter

© 2010 - 2020 WDDTY Publishing Ltd.
All Rights Reserved